BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:United Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies United Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03683186-524@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ralinepag: Phase 3 readout est. (NCT03683186)
DESCRIPTION:Ralinepag\, phase 3\, Pulmonary Arterial Hypertension.\nStudy: 
 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subje
 cts With PAH Via an Open-Label Extension\nEstimated primary completion: De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ralinepa
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 683186
URL:https://assetmemo.bio/drug/ralinepag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05943535-520@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Treprostinil (Tyvaso): Phase 3 readout est. (NCT05943535)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 3.\nStudy: Study of the Efficacy 
 and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary 
 Fibrosis (TETON-PPF)\nEstimated primary completion: November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05943535
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923591-520@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Treprostinil (Tyvaso): Phase 2 readout est. (NCT07923591)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2.\nStudy: Study of Treprostinil 
 Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hy
 pertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
 \nEstimated primary completion: May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07923591
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04905693-520@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Treprostinil (Tyvaso): Phase 3 readout est. (NCT04905693)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 3\, Idiopathic Pulmonary Fibrosis
 .\nStudy: Extension Study of Inhaled Treprostinil in Subjects With Fibroti
 c Lung Disease\nEstimated primary completion: December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04905693
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923526-520@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20340930
DTEND;VALUE=DATE:20341001
SUMMARY:Treprostinil (Tyvaso): Phase 2/3 readout est. (NCT07923526)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 2/3.\nStudy: An Open-Label Extens
 ion Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmon
 ary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH
 -COPD)\nEstimated primary completion: September 2034. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07923526
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
